InVivo Therapeutics EBITDA vs. Book Value Per Share

NVIVDelisted Stock  USD 1.38  0.07  5.34%   
Based on InVivo Therapeutics' profitability indicators, InVivo Therapeutics Holdings may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess InVivo Therapeutics' ability to earn profits and add value for shareholders.
For InVivo Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of InVivo Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well InVivo Therapeutics Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between InVivo Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of InVivo Therapeutics Holdings over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Please note, there is a significant difference between InVivo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if InVivo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InVivo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

InVivo Therapeutics Book Value Per Share vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining InVivo Therapeutics's current stock value. Our valuation model uses many indicators to compare InVivo Therapeutics value to that of its competitors to determine the firm's financial worth.
InVivo Therapeutics Holdings is rated below average in ebitda category among its peers. It is rated below average in book value per share category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value InVivo Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

InVivo Book Value Per Share vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

InVivo Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(9.8 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

InVivo Therapeutics

Book Value per Share

 = 

Common Equity

Average Shares

 = 
2.87 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

InVivo Book Value Per Share Comparison

InVivo Therapeutics is currently under evaluation in book value per share category among its peers.

InVivo Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in InVivo Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, InVivo Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of InVivo Therapeutics' change in net profit over the period of time. It can combine multiple indicators of InVivo Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. Invivo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.

InVivo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on InVivo Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of InVivo Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the InVivo Therapeutics' important profitability drivers and their relationship over time.

Use InVivo Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if InVivo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in InVivo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

InVivo Therapeutics Pair Trading

InVivo Therapeutics Holdings Pair Trading Analysis

The ability to find closely correlated positions to InVivo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace InVivo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back InVivo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling InVivo Therapeutics Holdings to buy it.
The correlation of InVivo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as InVivo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if InVivo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for InVivo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your InVivo Therapeutics position

In addition to having InVivo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Petroleum and Natural Gas Thematic Idea Now

Petroleum and Natural Gas
Petroleum and Natural Gas Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Petroleum and Natural Gas theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Petroleum and Natural Gas Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Consideration for investing in InVivo Stock

If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data